{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:13:37Z","timestamp":1788527617919,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000900","name":"CIRM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xjidi.2026.100520","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:41:38Z","timestamp":1785800498000},"page":"100520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demographic factors associated with response to topical Jak inhibitors in a diverse vitiligo cohort"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4477-813X","authenticated-orcid":false,"given":"Hira","family":"Rizwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3812-3572","authenticated-orcid":false,"given":"Britney T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1842-4871","authenticated-orcid":false,"given":"Anastasia","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1915-2482","authenticated-orcid":false,"given":"Thabat","family":"Dahdoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-8372","authenticated-orcid":false,"given":"Jessica","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100520_bib1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100520_bib2","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.xjidi.2026.100520_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2024.01.067","article-title":"Integrating skin color assessments into clinical practice and research: a review of current approaches","volume":"91","author":"Harvey","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100520_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdin.2025.08.016","article-title":"Topical 1.5% Ruxolitinib cream for facial refractory segmental vitiligo: a retrospective single-center study","volume":"24","author":"Huang","year":"2026","journal-title":"JAAD Int"},{"key":"10.1016\/j.xjidi.2026.100520_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","article-title":"Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy","volume":"56","author":"Nicolaidou","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100520_bib6","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100520_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568447","article-title":"Autoimmunity in segmental vitiligo","volume":"11","author":"Speeckaert","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100520_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2020.06.028","article-title":"Factors associated with insurance coverage of tofacitinib for alopecia areata: a retrospective review from an academic institution","volume":"83","author":"Thompson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100520_bib9","series-title":"Orange County, California","year":"2025"},{"key":"10.1016\/j.xjidi.2026.100520_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.fsc.2016.08.011","article-title":"Skin color and pigmentation in ethnic skin","volume":"25","author":"Visscher","year":"2017","journal-title":"Facial Plast Surg Clin North Am"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:20:03Z","timestamp":1788524403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2667026726000743"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100520","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic factors associated with response to topical Jak inhibitors in a diverse vitiligo cohort","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100520"}}